Abstract: A laser cutting method for a steel strip, includes cutting an end in a width direction of the steel strip including a joint obtained by joining a rear end of a preceding steel strip and a front end of a following steel strip by using a laser beam, wherein the steel strip is cut such that an interval between pieces of dross having an aspect ratio of 1.0 or more is set to 1.0 mm or more and an interval between dross having an aspect ratio of 1.0 or more and dross having an aspect ratio of less than 1.0 is set to 1.0 mm or more in the end in the width direction after cutting.

Abstract: A composite particle including carbon and silicon, in which the composite particle contains a crystalline metal oxide particle, and the end of the metal oxide particle is present inside the surface of the composite particle, and pores are present on the surface of the composite particle. According to the present invention, there can be provided a composite particle, in which silicon is attached to the inside of fine pores of a carbon material that has been provided with specific fine pores, the composite particle also contains a crystalline metal oxide particle, the end of the metal oxide particle is present inside the surface of the composite particle, and furthermore, pores are present on the surface of the composite particle. By using this composite particle, a lithium-ion secondary battery with excellent rate characteristics and cycle characteristics can be provided.

Abstract: One embodiment of the present invention is composite particles containing silicon and carbon, which are characterized as follows. When the cross-sectional diameter and the silicon content rate of the composite particles are measured by cross-sectional SEM-EDS and composite particles having a cross-sectional diameter of half or less than the number average of the cross-sectional diameter are defined as small diameter composite particles, the proportion of the number of the small diameter composite particles in the number of the composite particles measured is 5% or more and 50% or less, the ratio of the average silicon content rate (% by mass) of particles other than the small diameter composite particles to the average silicon content rate (% by mass) of the small diameter composite particles is 0.90 or less, and the silicon content rate of the entire composite particles is 45% by mass or more.

Abstract: A plurality of active filter devices (41, 42, 43) that each have an output connected to a harmonic-generating load device (2) and are capable of generating a compensating current for performing at least one of reduction of a harmonic current of the harmonic-generating load device (2) and improvement of the power factor of the fundamental wave are provided. The plurality of active filter devices (41, 42, 43) provide two or more types of capacities, and the number and combination of operating active filter devices among the active filter devices (41, 42, 43) change in accordance with the magnitude of the compensating current.

Abstract: An object of the present invention is to identify cancer antigen proteins specifically expressed on the surface of cancer cells and to provide a use of antibodies targeting such proteins as therapeutic and/or preventive agents for cancer. The present invention relates to, for example, a pharmaceutical composition for treatment and/or prevention of a cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with an MCEMP1 protein having an amino acid sequence shown in any one of the even numbered SEQ ID NOS: 2 to 8 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence, or with a fragment of the MCEMP1 protein comprising 7 or more consecutive amino acids.

Abstract: An object of the present invention is to identify cancer antigen proteins specifically expressed on the surface of cancer cells and to provide a use of antibodies targeting such proteins as therapeutic and/or preventive agents for cancer. The present invention relates to, for example, a pharmaceutical composition for treatment and/or prevention of a cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with an MCEMP1 protein having an amino acid sequence shown in any one of the even numbered SEQ ID NOS: 2 to 8 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence, or with a fragment of the MCEMP1 protein comprising 7 or more consecutive amino acids.

Abstract: A controller performs a first control for controlling the power source power factor or a power source harmonic of the harmonic current such that an input power factor of at least one of a plurality of connection devices changes in a direction preceding the power source power factor in a case where the power source power factor changes in a lagging direction, and performs a second control for controlling the power source power factor or the power source harmonic such that the input power factor of at least one of the connection devices changes in a direction lagging behind the power source power factor in a case where the power source power factor changes in a leading direction.

Abstract: A secondary battery having high electromotive force and including less lead or being free of lead is provided. The secondary battery includes a positive electrode including a positive electrode active material containing manganese oxide, a negative electrode including a negative electrode active material containing at least one selected from zinc, gallium, and tin, and an electrolytic solution containing at least one selected from phosphoric acid and organic oxoacid and having a pH of less than 7 at 25° C. This secondary battery has an open circuit voltage of more than 1.6 V in a fully charged state.

Abstract: The present invention relates to a novel immunity-inducing agent for treatment and/or prevention of cancer. Specifically, the present invention relates to an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity and selected from polypeptides derived from MRAP2 and modified forms thereof, or a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing the polypeptide in vivo, and a method for inducing immunity, comprising administering the immunity-inducing agent to a subject.

Abstract: A load apparatus is connected to an AC power source and is supplied with power from the AC power source. An operation state control unit controls, based on a target value about a power-source quality including either a power-source power factor of the AC power source or a power-source harmonic of the AC power source and on a present power-source quality, an operation state of the load apparatus.

Abstract: Provided are a halloysite powder and a method for producing the halloysite powder. The halloysite powder contains granules in which halloysite including halloysite nanotubes is aggregated. The granules have first pores derived from the tube holes in the halloysite nanotubes and second pores that are different from the first pores.

Abstract: An object of the present invention is to identify a cancer antigen protein specifically expressed on the surface of cancer cells and provide use of an antibody targeting the cancer antigen protein as a therapeutic and/or prophylactic agent for cancer. A pharmaceutical composition for treating and/or preventing cancer comprising an antibody or a fragment thereof having immunological reactivity with CSPG5 protein consisting of any one of amino acid sequences represented by SEQ ID NOs: 8, 4, 6, 10, and 12 and an amino acid sequence having an amino acid identity of 80% or more to the amino acid sequence, or a fragment thereof consisting of 7 or more consecutive amino acids, as an active ingredient.

Abstract: The present application relates to a novel immunity-inducing agent for treatment and/or prevention of cancer. Specifically, the present application provides an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity and selected from polypeptides derived from MCEMP1 and modified forms thereof, or a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing the polypeptide in vivo, and a method for inducing immunity, comprising administering the immunity-inducing agent to a subject.

Abstract: A controller performs a first control for controlling the power source power factor or a power source harmonic of the harmonic current such that an input power factor of at least one of a plurality of connection devices changes in a direction preceding the power source power factor in a case where the power source power factor changes in a lagging direction, and performs a second control for controlling the power source power factor or the power source harmonic such that the input power factor of at least one of the connection devices changes in a direction lagging behind the power source power factor in a case where the power source power factor changes in a leading direction.

Abstract: A current source capable of generating a current of a first compensation portion for either or both reducing a harmonic current in an air conditioner or improving a fundamental power factor in the air conditioner is provided. If an excess of the current source is larger than a second compensation portion for either or both reducing a harmonic current in a power receiving path of a distribution board or improving a fundamental power factor in the power receiving path of the distribution board, a current obtained through superimposition of a current of a second compensation component and a current of the first compensation component is generated in the current source.

Abstract: A secondary battery having high electromotive force and including less lead or being free of lead is provided. The secondary battery includes a positive electrode including a positive electrode active material containing manganese oxide, a negative electrode including a negative electrode active material containing at least one selected from zinc, gallium, and tin, and an electrolytic solution containing at least one selected from phosphoric acid and organic oxoacid and having a pH of less than 7 at 25° C. This secondary battery has an open circuit voltage of more than 1.6 V in a fully charged state.

Abstract: In a device with a built-in active filter, the device incorporating an active filter therein and being connected to an AC power source, the active filter operates based on a value detected by a load information detection unit detecting load information on an AC power source outside the device with a built-in active filter.

Abstract: A load apparatus is connected to an AC power source and is supplied with power from the AC power source. An operation state control unit controls, based on a target value about a power-source quality including either a power-source power factor of the AC power source or a power-source harmonic of the AC power source and on a present power-source quality, an operation state of the load apparatus.

Abstract: A plurality of active filter devices (41, 42, 43) that each have an output connected to a harmonic-generating load device (2) and are capable of generating a compensating current for performing at least one of reduction of a harmonic current of the harmonic-generating load device (2) and improvement of the power factor of the fundamental wave are provided. The plurality of active filter devices (41, 42, 43) provide two or more types of capacities, and the number and combination of operating active filter devices among the active filter devices (41, 42, 43) change in accordance with the magnitude of the compensating current.

Abstract: Provided are a halloysite powder having a novel granular structure not available in the prior art and a method for producing the halloysite powder. The halloysite powder contains granules in which halloysite including halloysite nanotubes is aggregated. The granules have first pores derived from the tube holes in the halloysite nanotubes and second pores that are different from the first pores.